Boehringer Ingelheim
High cure rate for Boehringer HCV drug
June 11, 2013Research and Development, Sales and Marketing Boehringer Ingelheim, HCV
One of Boehringer Ingelheim’s pipeline drugs has achieved high response rates in patients with chronic genotype-1 hepatitis C virus (HCV) in …
Boehringer unveils biopharma plant plan for China
June 6, 2013Manufacturing and Production Boehringer Ingelheim, China
Boehringer Ingelheim has said it intends to construct a cell-culture biopharmaceutical production facility in China offering contract R&D and manufacturing …
Boehringer and Lilly launch diabetes game
June 4, 2013Medical Communications Boehringer Ingelheim, combat, lilly
Boehringer Ingelheim and Eli Lilly have launched an educational digital game for type 2 diabetes called Complications Combat. The game …
Boehringer calls for ‘game changing’ ideas in health
January 29, 2013Medical Communications, Research and Development, Sales and Marketing Ashoka Changemakers, Boehringer Ingelheim
Boehringer Ingelheim has teamed up with a social entrepreneur network to promote health projects in developing countries. This is the …
Boehringer licenses high-pressure production technology
November 20, 2012Manufacturing and Production BaroFold, Boehringer Ingelheim
Boehringer Ingelheim has licensed a new technology from BaroFold which could improve the efficiency of biopharmaceutical production processes. Colorado, US-based …
Boehringer to increase production of Respimat inhaler
October 30, 2012Manufacturing and Production Boehringer Ingelheim, Respimat SMI, Soft Mist
Boehringer Ingelheim is investing €85 million in manufacturing capacity for its Respimat Soft Mist Inhaler in the face of growing …
Boehringer’s Engelbert Tjeenk Willink leaves firm
September 28, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, Engelbert Tjeenk Willink
Boehringer Board member Engelbert Tjeenk Willink, responsible for Marketing and Sales of Prescription Medicines, has decided to leave at the …
Trajenta added to insulin recommended in Europe
September 26, 2012Sales and Marketing Boehringer Ingelheim, Trajenta, diabetes
The CHMP has recommended that Boehringer Ingelheim and Eli Liily and Co’s diabetes brand Trajenta should be approved as add-on …
Pharma creates non-profit R&D organisation
September 21, 2012Research and Development, Sales and Marketing Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co, GlaxoSmithKline, Johnson & Johnson, Pfizer, R&D, Roche Genentech, Sanofi, TransCelerate BioPharma, biopharma
Ten biopharma companies have formed TransCelerate BioPharma Inc, a not-for-profit organisation using money and personnel from each firm, with a …
Working Life: Amanda Paxon
August 9, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amanda Paxon, Boehringer Ingelheim, Working Life
How did you find your way into your current role? Through a combination of good luck and hard work! I …
Boehringer wins contract to make Servier’s gevokizumab
August 7, 2012Manufacturing and Production Boehringer Ingelheim, CMO, Servier, antibody
Boehringer Ingelheim’s contract manufacturing organisation (CMO) division will provide commercial-scale manufacturing of a new monoclonal antibody developed by Servier and …
Boehringer Ingelheim makes changes to board
July 5, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim
Boehringer Ingelheim has appointed Dr Joachim Hasenmaier to its board of managing directors. The 52-year-old will take over responsibility for …
Boehringer appoints new executive director of Consumer Healthcare Marketing
May 31, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim
Boehringer Ingelheim has announced the appointment of Ross Ullman as the executive director marketing of the Consumer Healthcare division. In …
A family business: Pradaxa success lifts Boehringer
April 25, 2012Research and Development, Sales and Marketing Boehringer Ingelheim
Rapid uptake of anti-clotting drug Pradaxa in the US has helped Boehringer Ingelheim enjoy a strong year, and looks set to …
Latest content
Five Facts about cardiovascular disease
